More than half of radiologists are concerned about contrast agent availability, according to a survey conducted by Bracco Diagnostics.
The company found that 55% of 200 radiologists surveyed have concerns about the availability of gadolinium-based contrast agents (GBCAs) for use with MRI exams. Bracco performed the survey in collaboration with global medical research firm Sermo between October and November of this year.
Radiologists working at small hospitals were the most concerned (75%), compared with those at larger institutions (35%). More than two-thirds of survey participants (63%) stressed the importance of manufacturing contrast agents in the U.S.
The survey found that factors such as patient safety, image quality, and contrast supply availability were more important to participants in terms of maintaining the health of their practices than generating revenue, training staff, and implementing sustainable protocols.
Additionally, the survey found the following:
- 99% of participants would be interested in using an MRI contrast agent containing half the gadolinium.
- 26% of radiologists experienced issues with the availability of gadolinium-based contrast agents in the past few years.
- 35% stated that their patients express concerns about MRI contrast agents used in their bodies. 41% said their patients are more informed about MRI contrast agents than just a few years ago.
- 35% stated they are thinking about environmental impact and sustainability more than they did a few years ago.
Most of the survey respondents work in hospital settings (147), although radiologists working in imaging centers (40) and outpatient departments (13) were also represented, Bracco said.